Syngene International is India’s first and largest integrated contract research, development, and manufacturing organization - a one-stop scientific engine room where global pharma and biotech companies outsource everything from early drug discovery to commercial production. Founded in 1993 by Kiran Mazumdar-Shaw as a pure research shop and still majority-owned by Biocon Limited, the company spent three decades steadily adding development and manufacturing muscle, transforming from a chemistry lab into a balanced CRDMO with over 3 million square feet of infrastructure and roughly 400 active clients. The recurring logic is forward integration: Syngene wins a client with research services, then follows the molecule downstream into development and manufacturing, capturing more of the value chain as the drug advances.
Business segments
A single integrated CRDMO platform with two growth engines - research services and development/manufacturing - that feed each other as molecules move from discovery to commercial supply.
1. Research Services: the discovery engine that feeds the pipeline
Clients outsource their earliest-stage drug hunting here, paying for dedicated scientist teams or per-project work, and the intellectual property stays with them - Syngene is the lab, not the inventor.
- Paid by the scientist or the project - engagements run on Full-Time Equivalent (FTE) arrangements where dedicated scientific resources work on client projects with agreements typically renewed annually, or Fee-for-Service (FFS) for defined-scope work; outcome-based and risk/reward models also exist, but intellectual property is always fully assigned to the client.
- Dedicated R&D centers lock in long-term revenue - three ring-fenced facilities operate as turn-key extensions of Bristol-Myers Squibb, Amgen, and Baxter, with client representatives co-located on premises; these are typically five-year-plus strategic partnerships that provide predictable cash flows and revenue visibility over the medium to long term. The BMS center alone houses over 600 scientists and has produced more than 10 drug candidates for further study, with the collaboration extended through 2035.
- AI and proprietary platforms sharpen the offering - Syn.AI, the company’s AI-enabled platform, accelerates data-driven research and predictive insights across the discovery workflow, while proprietary tools like SynVent (integrated drug discovery) and SynTACs (targeted degradation) give clients access to capabilities they would struggle to build in-house.
- Early clinical trials are part of the package - the Translational & Clinical Research unit runs a 190-bed Human Pharmacology Unit for Phase I and bioequivalence studies, has completed 800 BA/BE studies for regulated-market submissions, and initiated its first global Phase 3 trial, so clients can stay with Syngene right through to first-in-human data.
2. Development and Manufacturing - Small Molecules: from lab recipe to factory output
Once a drug candidate shows promise, this division scales the chemistry into compliant, commercial-ready manufacturing - making the active ingredient and the finished pill under one roof.
- Follow-the-molecule integration - the division was restructured to combine development and manufacturing into a single unit, so a client’s molecule moves seamlessly from route scouting and process development through clinical supplies to sustained commercial production without handoffs between separate teams.
- Regulatory-ready manufacturing - the USFDA-compliant API facility in Mangaluru has approvals from US, European, and UK regulators and passed a July 2023 FDA inspection with zero observations, meaning clients can file for drug approvals using material made here.
- China-plus-one tailwind - the company intends to manufacture Key Starting Materials and Regulatory Starting Materials in the medium term, positioning itself as an alternative supply-chain node for global pharma customers pursuing dual-sourcing strategies away from China.
3. Development and Manufacturing - Large Molecules: biologics at scale, built through acquisition
Biologics are complex, fermentation-grown drugs, and Syngene now operates a transcontinental manufacturing network with capacity to produce them from cell line to filled vial.
- Bought, not just built - two acquisitions transformed the division: Unit 3 in Bengaluru (acquired from Stelis Biopharma in 2023) added 20,000 liters of installed biologics drug substance capacity plus a commercial-scale fill-finish unit, while the Bayview facility in Maryland, USA (acquired from Emergent) added single-use bioreactor capacity and a US operational base, taking total global single-use bioreactor capacity to 50,000 liters once fully integrated.
- Single-use technology for speed and safety - both the Bengaluru and Bayview facilities use single-use bioreactors, which offer greater flexibility, faster changeovers between products, and lower risk of lot-to-lot contamination compared to traditional stainless-steel systems.
- A decade-long anchor contract - a 10-year manufacturing agreement with Zoetis for the osteoarthritis drug Librela (a monoclonal antibody for dogs) reached its full run-rate of USD 50 million per annum in FY24, demonstrating the long-cycle nature of the business where client engagement begins with process R&D years before commercial supply starts.
- Cost leadership is the explicit goal - the division targets being the most cost-efficient manufacturer per gram by combining a high-performing cell line (target titer of 5-10 g/L), process intensification that delivered a three-to-four-fold increase in titer, and a 10% reduction in cost of goods sold through alternate resins and filters, with plans for a further 40% reduction.
4. Antibody Drug Conjugates: the bridge between small and large molecules
ADCs - cancer therapies that link a targeting antibody to a toxic payload - sit at the intersection of Syngene’s two manufacturing worlds, and the company has built an integrated discovery-to-manufacturing chain for them at a single site.
- One site, one chain - a GMP bioconjugation suite at Unit 3 in Bengaluru complements existing payload and linker manufacturing, so clients can go from antibody production through conjugation to finished ADC without leaving Syngene’s ecosystem.
- Riding a modality wave - novel modalities like ADCs now account for over 40% of clinical pipelines and are growing faster than traditional small molecules, making the ADC platform a bet on where the industry’s R&D spending is heading.
Group structure and partners
Syngene is an operationally independent public company with Biocon as its 53% promoter, supported by three wholly owned subsidiaries and a web of long-term strategic alliances that provide both revenue visibility and capability reach.
- US subsidiary holds the American beachhead - Syngene USA Inc., incorporated in Delaware, provides marketing services and owns the Bayview biologics manufacturing facility in Maryland, giving the company a direct operational and regulatory presence in the world’s largest pharma market.
- Two Indian subsidiaries, one in wind-down - Syngene Scientific Solutions Limited runs the Hyderabad research operations transferred via a slump sale in 2023, while Syngene Manufacturing Solutions Limited never commenced operations and its board approved a proposal for voluntary liquidation in May 2026.
- Anchor partnerships span decades - the Bristol-Myers Squibb collaboration, now extended through 2035, is a 25-year relationship covering discovery, development, manufacturing, and clinical trials; Amgen’s dedicated center runs to end-2026 with a new lab being built for small-molecule scale-up; and the Zoetis biologics contract is worth up to USD 500 million over 10 years.
- Renewable energy stakes secure captive power - minority holdings in three solar and wind-solar hybrid special purpose vehicles (ranging from 8% to 34%) help meet green energy needs while maintaining captive status under the Electricity Act.